Journal article
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
- Abstract:
-
Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated schedule provides additional benefit to a single dose. We randomized 852 older adults (median age, 68-years) with AML/high-risk myelodysplasia to GO on day 1 (GO1) or on days 1 and 4 (GO2) of course 1 induction. The median follow-up period was 50.2 months. Although complete remission (CR) rates afte...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.2MB, Terms of use)
-
- Publisher copy:
- 10.1182/blood.2023020630
Authors
Bibliographic Details
- Publisher:
- American Society of Hematology
- Journal:
- Blood More from this journal
- Volume:
- 142
- Issue:
- 20
- Pages:
- 1697-1707
- Publication date:
- 2023-08-18
- Acceptance date:
- 2023-08-08
- DOI:
- EISSN:
-
1528-0020
- ISSN:
-
0006-4971
- Pmid:
-
37595359
Item Description
- Language:
-
English
- Keywords:
-
- Pubs id:
-
1512471
- Local pid:
-
pubs:1512471
- Deposit date:
-
2023-11-15
Terms of use
- Copyright holder:
- Freeman et al.
- Copyright date:
- 2023
- Rights statement:
- Copyright © 2023 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record